Canaan Partners is an early-stage venture firm investing primarily at Seed and Series A across technology and healthcare, with a long-standing bias toward being the first institutional partner. The firm emphasizes backing exceptional founders in large markets, applying valuation discipline, and reserving significant capital to support breakout companies over time.
Canaan Partners bases its investment decisions on three core pillars: (1) go as early as possible, (2) partner closely with founders for the long haul, and (3) target large market opportunities with exceptional teams. The firm’s Fund XII and Fund XIII announcements repeatedly stress the importance of being the "very first" partner and maintaining sizeable reserves to double‑down on winners. In technology, they look for strong market pull—particularly in cybersecurity, AI/ML infrastructure, and frontier tech—and apply a pricing discipline of backing winners at reasonable valuations. In healthcare, they prioritize evidence‑driven, science‑forward opportunities in oncology, immunology, neurology, cardiology and respiratory, especially new modalities and precision approaches. The decision process heavily weighs founder passion and capability, followed by market size and early traction. Deal‑breakers include high‑momentum pricing without clear sustainable advantage or insufficient market pull. When conviction is high, Canaan will incubate and lead, as shown by the $10M seed for Bond, leveraging its reserve pool to increase ownership in breakout companies.
See the rest of how Canaan Partners decides.
Evaluation framework, investment themes, pitch guidance and the partner map. One email, no password — we send a link and you land right back here.